Plasma PrPC and ADAM-10 as novel biomarkers for traumatic brain injury and concussion: a pilot study.
ADAM-10
biomarker
cellular prion protein
concussion
traumatic brain injury
Journal
Brain injury
ISSN: 1362-301X
Titre abrégé: Brain Inj
Pays: England
ID NLM: 8710358
Informations de publication
Date de publication:
12 05 2021
12 05 2021
Historique:
pubmed:
25
3
2021
medline:
10
8
2021
entrez:
24
3
2021
Statut:
ppublish
Résumé
Cellular prion protein (PrPC) is a lipid raft protein abundant within CNS. It is regulated by a disintegrin and metalloproteinase domain containing protein 10 (ADAM10). PrPC has previously been implicated as a biomarker for TBI. ADAM10 has not been investigated as a TBI biomarker. We evaluated PrPC and ADAM10 as candidate biomarkers for TBI. We performed ELISA for ADAM10 and PrPC on plasma samples of patients with TBI admitted to Brigham and Women's Hospital. Plasma samples from 20 patients admitted for isolated TBI were acquired from a biobank with clinical information. Control plasma (37 samples) was acquired from a commercial source. GraphPad was used to conduct statistical analysis. 37 controls and 20 TBI samples were collected. Of the patients with TBI, eight were mild, three were moderate, and nine were severe. Both PrPC and ADAM10 were elevated in patients with TBI compared with control ( Our results indicate that PrPC and ADAM10 appear to be useful potential tools for screening of TBI. ADAM10 is closely associated with clinical grade.
Sections du résumé
BACKGROUND
Cellular prion protein (PrPC) is a lipid raft protein abundant within CNS. It is regulated by a disintegrin and metalloproteinase domain containing protein 10 (ADAM10). PrPC has previously been implicated as a biomarker for TBI. ADAM10 has not been investigated as a TBI biomarker.
OBJECTIVE
We evaluated PrPC and ADAM10 as candidate biomarkers for TBI.
METHODS
We performed ELISA for ADAM10 and PrPC on plasma samples of patients with TBI admitted to Brigham and Women's Hospital. Plasma samples from 20 patients admitted for isolated TBI were acquired from a biobank with clinical information. Control plasma (37 samples) was acquired from a commercial source. GraphPad was used to conduct statistical analysis.
RESULTS
37 controls and 20 TBI samples were collected. Of the patients with TBI, eight were mild, three were moderate, and nine were severe. Both PrPC and ADAM10 were elevated in patients with TBI compared with control (
CONCLUSIONS
Our results indicate that PrPC and ADAM10 appear to be useful potential tools for screening of TBI. ADAM10 is closely associated with clinical grade.
Identifiants
pubmed: 33760683
doi: 10.1080/02699052.2021.1900602
doi:
Substances chimiques
Biomarkers
0
Membrane Proteins
0
Prion Proteins
0
Prions
0
Amyloid Precursor Protein Secretases
EC 3.4.-
ADAM10 Protein
EC 3.4.24.81
ADAM10 protein, human
EC 3.4.24.81
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM